60159-37-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Chloropyridin-2-yl)ethanone is used as a key intermediate for the synthesis of pyridylalkylamines, which are important building blocks in the development of pharmaceuticals with diverse therapeutic applications, such as antidepressants, antipsychotics, and antiparkinsonian agents.
Used in Agrochemical Industry:
1-(4-Chloropyridin-2-yl)ethanone is also utilized as a precursor in the synthesis of agrochemicals, specifically in the production of insecticides and herbicides. Its unique structural features contribute to the development of novel compounds with improved efficacy and selectivity in controlling pests and weeds.
Used in Asymmetric Synthesis:
1-(4-Chloropyridin-2-yl)ethanone is a useful reagent for the asymmetric synthesis of pyridylalkylamines. This application is significant in the field of organic chemistry, as it allows for the selective formation of enantiomerically pure compounds, which is crucial for the development of drugs with improved safety and efficacy profiles.

Upstream product

• 19235-89-3 4-chloro-pyridine-2-carbonitrile 
• 917-64-6 methyl magnesium iodide 
• 75-16-1 methylmagnesium bromide 
• 5470-66-6 2-methyl-4-nitropyridine N-oxide 

Downstream Products

• 121638-26-4 (+/-)-4-chloro-2-(1-hydroxyethyl)pyridine 
• 1278596-23-8 C₂₂H₂₂BF₄N₃O₃ 
• 1278596-21-6 C₁₅H₈ClF₄N₃O 
• 1278596-20-5 C₁₅H₁₀ClF₄N₃O₂ 

Relevant academic research and scientific papers

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Pyridylpyrazole N∧N ligands combined with sulfonyl-functionalised cyclometalating ligands for blue-emitting iridium(III) complexes and solution-processable PhOLEDs

A series of blue iridium(iii) complexes (12-15) comprising sulfonyl-functionalised phenylpyridyl cyclometalating ligands and pyridylpyrazole N^N ligands are reported, with an X-ray crystal structure obtained for 12. The complexes are highly emissive with photoluminescence quantum yields of 0.52-0.70 in dichloromethane solutions: two of the complexes (12 and 14) show emissions at λPLmax 457 nm which is considerably blue-shifted compared to the archetypal blue emitter FIrpic (λmax 468 nm). The short excited state lifetimes (1.8-3.3 μs) and spectral profiles are consistent with phosphorescence from a mixture of ligand-centred and MLCT excited states. Density functional (DFT) and time dependent DFT (TD-DFT) calculations are in agreement with the electrochemical properties and the blue phosphorescence of the complexes. The additional mesityl substituent on the pyridylpyrazole ligand of 12 and 13 enhances the solubility of the complexes facilitating thin film formation by solution processing. Phosphorescent organic light-emitting diodes (PhOLEDs) have been fabricated using 12 or 13 in a solution-processed single-emitting layer using either poly(vinylcarbazole) (PVK) or 1,3-bis(N-carbazolyl)benzene (mCP) as host. The most blue-shifted electroluminescence (λELmax 460 nm, CIEx,y 0.15, 0.21) is obtained for an OLED containing complex 12 and mCP, with a brightness of 5400 cd m-2 at 10 V which is high for PhOLEDs with similar blue CIE coordinates using a solution-processed emitter layer.

PYRIDINYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF PI3 KINASES

Compounds of the formula (I), in which X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, R10 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours.

Biocatalytic preparation of optically active 4-(N,N-dimethylamino)pyridines for application in chemical asymmetric catalysis

4-Chloro-2-(1-hydroxybenzyl)pyridine and 4-chloro-2-(1-hydroxyalkyl)pyridines were obtained with moderate to excellent enantiomeric excesses and high isolated yields by bioreduction with Baker's yeast of the corresponding ketones. The resulting optically active alcohols were transformed into adequate DMAP derivatives, which have been applied in asymmetric catalytic processes as nucleophilic catalysts in the stereoselective chemical alkoxycarbonylation of 1-phenylethanol or as chiral ligands in the enantioselective addition of diethylzinc to benzaldehyde.

Chemoenzymatic synthesis of chiral 4-(N,N-dimethylamino)pyridine derivatives

Chiral 4-(N,N-dimethylamino)pyridine derivatives have been prepared through a chemoenzymatic synthesis where the enzymatic kinetic resolution of a family of 4-chloro-2-(1-hydroxyalkyl)pyridines is the key step for the formation of potentially important chiral catalysts. Pseudomonas cepacia lipase (PSL) showed excellent enantioselectivity in the acylation of the (R)-enantiomers (E > 200) using vinyl acetate as acylating agent and THF as solvent, obtaining products and substrates enantiomerically pure and with excellent yields.

2,3-substituted indole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.

Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is tetrazolyl optionally substituted with a substituent selected from C1-4 alkyl and halosubstituted C1-4 alkyl;A is C1-6 alkylene; Q is selected from the following groups: (a) optionally substituted phenyl; (b) an optionally substituted, partially saturated, fully saturated or fully unsaturated five to six membered monocyclic group having one to three heteroatoms; and (c) an optionally substituted, bicyclic group consisting of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings independently and optionally having one to four heteroatoms; X is halogen, C1-4 alkyl, halosubstituted C1-4 alkyl, OH, C1-4 alkoxy or the like; and n is 0, 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.